Brind.
  1. FDA-approved products are being moved to Schedule III following a rescheduling order finalized by the DOJ and DEA, involving Curaleaf.

Curaleaf prepares for US exchange uplisting as DEA rescheduling deadlines drive ETF performance and regulatory reclassification.

1 report, 1 independent Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Curaleaf prepares for US exchange uplisting as DEA rescheduling deadlines drive ETF performance and regulatory reclassification.

Who's involved

What this event is mainly about
CuraleafDrug Enforcement Administration

Keep exploring

Part of

FDA-approved products are being moved to Schedule III following a rescheduling order finalized by the DOJ and DEA, involving Curaleaf. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped